pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Hematology · news · pharmadog
← back to Hematology
News · Hematology
406
stories
6d
ICER says AstraZeneca’s new blood pressure med isn’t cost-effective
endpoints
6d
STAT+: Pharmalittle: We’re reading about a lawsuit over lab tests for meds, a Bristol myeloma drug, and more
stat
6d
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
biopharma dive
6d
STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
stat
7d
Zealand sells milestone, royalty rights to rare blood cancer asset for up to $100M
biospace
8d
Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision
fiercebiotech
8d
Opinion: The Lindsay Clancy case shows the limits of postpartum psychiatry
stat
8d
Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines
biopharma dive
8d
Opinion: Climate change is making people with chronic illness even sicker
stat
9d
Stopping statins in people over 75 at low risk for heart disease didn’t increase deaths
stat
9d
Silence causes uproar in rare blood cancer space as data sets high bar for competitors
biospace
9d
Vaderis gets $152M to run Phase 3 of rare bleeding disorder treatment
endpoints
9d
Vaderis hauls in $152M to test an AKT-targeting drug
biopharma dive
9d
Zydus’ Sentynl pens $475M deal for Mereo’s phase 3-ready rare genetic lung disease drug
fiercebiotech
9d
After tasting IPO success, Hemab’s CEO seeks ‘flavor of a multi-product coagulation company’
fiercebiotech
10d
Abbott teams with Google Health on AI-powered health insights app
fiercebiotech
10d
BMS picks Texas for new $2.3B manufacturing campus
biospace
10d
STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment
stat
10d
STAT+: FDA panel to weigh Grail’s Galleri test
stat
10d
‘We are proud to be in the lead’: Vaderis lands $152M for phase 3 study in rare blood vessel disorder
fiercebiotech
10d
STAT+: Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial
stat
10d
STAT+: Heart failure drug from Tenax Therapeutics fails in pivotal study
stat
10d
Silence spells out Phase 2 success for gene-silencing drug in rare blood cancer
endpoints
10d
STAT+: Silence Therapeutics aims at Takeda with new data in rare blood cancer
stat
10d
Denali climbs past Avlayah expectations with $3.6M in revenue
biospace
10d
FDA issues alert in wake of BD recall of faulty needle sets
fiercebiotech
11d
Silence brings the noise to Takeda with phase 2 blood cancer win
fiercebiotech
11d
Fresenius Kabi Issues Nationwide Recall of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials Due to Presence of Glass Particles
fda recalls
11d
Catheter Introducer Correction: Abiomed and Oscor Issue Correction for Catheter Introducer
fda medwatch
13d
Why Big Pharma is chasing the industry’s most-powerful supercomputer
biopharma dive
← prev
page 2 of 14
next →
